[
  {
    "ts": null,
    "headline": "Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment",
    "summary": "Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.",
    "url": "https://finnhub.io/api/news?id=25a4a09bb9b30921d3e256bb6f0d7482eb1a5f4b1f4bedfdcc31a0b21f76fac2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732659390,
      "headline": "Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment",
      "id": 131654555,
      "image": "",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.",
      "url": "https://finnhub.io/api/news?id=25a4a09bb9b30921d3e256bb6f0d7482eb1a5f4b1f4bedfdcc31a0b21f76fac2"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones, S&P 500 At New High After Fed Minutes; Dell, Workday, CrowdStrike Report (Live Coverage)",
    "summary": "The Dow Jones Industrial Average fell after news that President-elect Trump may impose tariffs on goods from China, Mexico and Canada.",
    "url": "https://finnhub.io/api/news?id=ae28b3786a8297ac29cb4dfcdf8d23b109d0ef2f794d7d35345dba1755b03045",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732656025,
      "headline": "Dow Jones, S&P 500 At New High After Fed Minutes; Dell, Workday, CrowdStrike Report (Live Coverage)",
      "id": 131654556,
      "image": "https://media.zenfs.com/en/ibd.com/654b9ec0cb4588c07c8ac00e56fa3ea9",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average fell after news that President-elect Trump may impose tariffs on goods from China, Mexico and Canada.",
      "url": "https://finnhub.io/api/news?id=ae28b3786a8297ac29cb4dfcdf8d23b109d0ef2f794d7d35345dba1755b03045"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline",
    "summary": "Shares of Amgen (AMGN) fell on Tuesday after the biotech company reported results for a phase 2 study of its obesity injection, which fell short of efficacy expectations, Mizuho Securities said.",
    "url": "https://finnhub.io/api/news?id=cb427ab71d5546d78ec3986967931a478970412cb3940d2c2a697fc342c30519",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732654806,
      "headline": "Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline",
      "id": 131654557,
      "image": "https://media.zenfs.com/en/mt_newswires_premium_news_706/d70bfd97d34d91f243bedfdbb8f65779",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Shares of Amgen (AMGN) fell on Tuesday after the biotech company reported results for a phase 2 study of its obesity injection, which fell short of efficacy expectations, Mizuho Securities said.",
      "url": "https://finnhub.io/api/news?id=cb427ab71d5546d78ec3986967931a478970412cb3940d2c2a697fc342c30519"
    }
  },
  {
    "ts": null,
    "headline": "Amgen share price plummets despite Phase II weight loss success",
    "summary": "Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had hoped for more.",
    "url": "https://finnhub.io/api/news?id=cb3ecd5ff64e53b3c12b156d084764f2ce9b504f603945abc92a2cb1057c445c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732647834,
      "headline": "Amgen share price plummets despite Phase II weight loss success",
      "id": 131654558,
      "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/11/shutterstock_2179492463.jpg",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had hoped for more.",
      "url": "https://finnhub.io/api/news?id=cb3ecd5ff64e53b3c12b156d084764f2ce9b504f603945abc92a2cb1057c445c"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations",
    "summary": "A Phase 2 study of Amgen's experimental weight-loss treatment didn't meet expectations of analysts.",
    "url": "https://finnhub.io/api/news?id=5eaadc759032fc710acc4c761436fca7d0d3dfcc28be5f8912470dbf10a28f60",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732645724,
      "headline": "Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations",
      "id": 131654560,
      "image": "https://www.investopedia.com/thmb/e4DsbojGdXVOQ5XUT0yAE0HaGzQ=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1491079794-476146ea03bc4bed9fe981d3e552dac4.jpg",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "A Phase 2 study of Amgen's experimental weight-loss treatment didn't meet expectations of analysts.",
      "url": "https://finnhub.io/api/news?id=5eaadc759032fc710acc4c761436fca7d0d3dfcc28be5f8912470dbf10a28f60"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.",
    "summary": "The pharmaceutical company's MariTide treatment performs well in a phase 2 study but not as well as Wall Street expected.",
    "url": "https://finnhub.io/api/news?id=47b7084b776006df8e5efa828620d88406041fdd1c5ab7bbc2c3f752e365faec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732633440,
      "headline": "Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.",
      "id": 131643460,
      "image": "",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The pharmaceutical company's MariTide treatment performs well in a phase 2 study but not as well as Wall Street expected.",
      "url": "https://finnhub.io/api/news?id=47b7084b776006df8e5efa828620d88406041fdd1c5ab7bbc2c3f752e365faec"
    }
  },
  {
    "ts": null,
    "headline": "Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed",
    "summary": "Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed.",
    "url": "https://finnhub.io/api/news?id=602dc03bbd11ec22b5b08d98996bf9617b1f088d0df4fe5a7b8de58612f63a6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732644109,
      "headline": "Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed",
      "id": 131654563,
      "image": "https://media.zenfs.com/en/quartz.com/df63737770727d5fee89278a66c26050",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed.",
      "url": "https://finnhub.io/api/news?id=602dc03bbd11ec22b5b08d98996bf9617b1f088d0df4fe5a7b8de58612f63a6f"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: Amgen, Best Buy, JM Smucker, and More",
    "summary": "U.S. equities were mixed at midday following comments from President-elect Trump about new tariffs on Chinese, Canadian, and Mexican imports.",
    "url": "https://finnhub.io/api/news?id=38df83cd208be361548e1bacba51b537a49b445f32833e9cbfd0ba3bfdbfaaae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732640623,
      "headline": "Top Stock Movers Now: Amgen, Best Buy, JM Smucker, and More",
      "id": 131648572,
      "image": "https://www.investopedia.com/thmb/OrhAdp6InfEu5Ay9ndmJRByRKWk=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1491081305-af5268c668254a858ffbdff7f23ff560.jpg",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "U.S. equities were mixed at midday following comments from President-elect Trump about new tariffs on Chinese, Canadian, and Mexican imports.",
      "url": "https://finnhub.io/api/news?id=38df83cd208be361548e1bacba51b537a49b445f32833e9cbfd0ba3bfdbfaaae"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Automaker Shares Fall on New Trump Tariff Threat; Amgen Shares Tumble on Obesity Drug Study Results",
    "summary": "The Nasdaq Composite and S&P 500 Index were both up in late-morning trading Tuesday, while the Dow Jones Industrial Average was down, as Wall Street assesses the potential impact of tariffs promised by President-elect Donald Trump.",
    "url": "https://finnhub.io/api/news?id=d49c5c9eedd2573786d2cc83f9eb307c8a8282fa227ab9fe737d446cc5defb51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732640253,
      "headline": "Top Midday Stories: Automaker Shares Fall on New Trump Tariff Threat; Amgen Shares Tumble on Obesity Drug Study Results",
      "id": 131648360,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The Nasdaq Composite and S&P 500 Index were both up in late-morning trading Tuesday, while the Dow Jones Industrial Average was down, as Wall Street assesses the potential impact of tariffs promised by President-elect Donald Trump.",
      "url": "https://finnhub.io/api/news?id=d49c5c9eedd2573786d2cc83f9eb307c8a8282fa227ab9fe737d446cc5defb51"
    }
  },
  {
    "ts": null,
    "headline": "Amgen stock slips as obesity drug study disappoints Wall Street",
    "summary": "Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly obesity drug MariTide. Despite the medication demonstrating the ability to reduce an individual's body weight by 20%, the stock tumbled as the results fell short of investor expectations. Yahoo Finance Health Reporter Anjalee Khemlani delves into the details of the study, exploring the potential strategic routes Amgen could pursue to position the drug competitively in the growing GLP-1 weight loss market. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Angel Smith",
    "url": "https://finnhub.io/api/news?id=585005f4ceea4e8cce6ee087ae3deea5b1f597c2078eb934768086c7e8343572",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732640192,
      "headline": "Amgen stock slips as obesity drug study disappoints Wall Street",
      "id": 131654566,
      "image": "https://s.yimg.com/ny/api/res/1.2/cB2UsKYlllZ5DWVmbbsT5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-11/532ce7f0-ac14-11ef-9dfb-dd4d7e35bfdc",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly obesity drug MariTide. Despite the medication demonstrating the ability to reduce an individual's body weight by 20%, the stock tumbled as the results fell short of investor expectations. Yahoo Finance Health Reporter Anjalee Khemlani delves into the details of the study, exploring the potential strategic routes Amgen could pursue to position the drug competitively in the growing GLP-1 weight loss market. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Angel Smith",
      "url": "https://finnhub.io/api/news?id=585005f4ceea4e8cce6ee087ae3deea5b1f597c2078eb934768086c7e8343572"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Falls as Weight-Loss Shot  Results Disappoint Street",
    "summary": "(Bloomberg) -- Amgen Inc. shares fell the most in 23 years after its experimental obesity shot failed to outperform those of rivals and showed a high rate of side effects.Most Read from BloombergNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldNYC's Underground Steam System May Be Key to a Greener FutureNYC Gets Historic Push for 80,000 Homes With $5 Billion PledgeThe reaction shows how high the bar is for",
    "url": "https://finnhub.io/api/news?id=46459a8f1bdb79e32f7a70432875bbef3a492b7242cebd9b1235aeda2eb66aef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732631920,
      "headline": "Amgen Falls as Weight-Loss Shot  Results Disappoint Street",
      "id": 131643464,
      "image": "https://s.yimg.com/ny/api/res/1.2/J1C3rZnBRECLRjxOrGLO.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/4f42fa846d08ca07e91a458445768199",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Amgen Inc. shares fell the most in 23 years after its experimental obesity shot failed to outperform those of rivals and showed a high rate of side effects.Most Read from BloombergNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldNYC's Underground Steam System May Be Key to a Greener FutureNYC Gets Historic Push for 80,000 Homes With $5 Billion PledgeThe reaction shows how high the bar is for",
      "url": "https://finnhub.io/api/news?id=46459a8f1bdb79e32f7a70432875bbef3a492b7242cebd9b1235aeda2eb66aef"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Falls On Trump Tariff Risk As Fed Minutes Loom; Nvidia Rises But Retailers Dive On Earnings (Live Coverage)",
    "summary": "Dow Jones Falls On Trump Tariff Risk As Fed Minutes Loom; Nvidia Rises But Retailers Dive On Earnings (Live Coverage)",
    "url": "https://finnhub.io/api/news?id=3db4041a4adb9438df83b58ca4ea53f98137802a0520da639c53c4313296827d",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732617445,
      "headline": "Dow Jones Falls On Trump Tariff Risk As Fed Minutes Loom; Nvidia Rises But Retailers Dive On Earnings (Live Coverage)",
      "id": 131640255,
      "image": "",
      "related": "AMGN",
      "source": "DowJones",
      "summary": "Dow Jones Falls On Trump Tariff Risk As Fed Minutes Loom; Nvidia Rises But Retailers Dive On Earnings (Live Coverage)",
      "url": "https://finnhub.io/api/news?id=3db4041a4adb9438df83b58ca4ea53f98137802a0520da639c53c4313296827d"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Obesity Drug Cut Weight In Closely Watched Study",
    "summary": "A highly anticipated obesity-drug candidate from biotech  Amgen  helped patients shed a significant amount of weight in a midstage study.  Subjects taking Amgen’s MariTide lost 20% of their body weight compared with those who received placebos, Amgen said Tuesday.  Analysts had generally expected the drug to achieve weight reduction of 20% or more.",
    "url": "https://finnhub.io/api/news?id=8a0d16aaa6995e198f7435caf98cb20babfdcde9e04af972b02869946c0b9ce7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732624440,
      "headline": "Amgen Obesity Drug Cut Weight In Closely Watched Study",
      "id": 131643468,
      "image": "",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "A highly anticipated obesity-drug candidate from biotech  Amgen  helped patients shed a significant amount of weight in a midstage study.  Subjects taking Amgen’s MariTide lost 20% of their body weight compared with those who received placebos, Amgen said Tuesday.  Analysts had generally expected the drug to achieve weight reduction of 20% or more.",
      "url": "https://finnhub.io/api/news?id=8a0d16aaa6995e198f7435caf98cb20babfdcde9e04af972b02869946c0b9ce7"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: MariTide Underwhelms, But There Are Ways To Win",
    "summary": "Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.",
    "url": "https://finnhub.io/api/news?id=e675d5c22ba1ea503e4682d6afacf863c2ac54b08fcfb4811b0184c18ee778b6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732633388,
      "headline": "Amgen: MariTide Underwhelms, But There Are Ways To Win",
      "id": 131651601,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2162809200/image_2162809200.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.",
      "url": "https://finnhub.io/api/news?id=e675d5c22ba1ea503e4682d6afacf863c2ac54b08fcfb4811b0184c18ee778b6"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Open Mixed. Amgen Is Dragging on the Dow.",
    "summary": "Stocks were mixed to start the day on Tuesday as markets reacted to a wave of earnings reports and economic data.  There’s also President-elect Donald Trump’s plans for tariffs on Mexico, Canada, and China for Wall Street to digest.  The Dow Jones Industrial Average was down 157 points, or 0.4%.",
    "url": "https://finnhub.io/api/news?id=7baa880928ef0a799c9a21315c40e2012d5927b781b6f0756aa937ddc227d792",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732631621,
      "headline": "Stocks Open Mixed. Amgen Is Dragging on the Dow.",
      "id": 131640991,
      "image": "",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Stocks were mixed to start the day on Tuesday as markets reacted to a wave of earnings reports and economic data.  There’s also President-elect Donald Trump’s plans for tariffs on Mexico, Canada, and China for Wall Street to digest.  The Dow Jones Industrial Average was down 157 points, or 0.4%.",
      "url": "https://finnhub.io/api/news?id=7baa880928ef0a799c9a21315c40e2012d5927b781b6f0756aa937ddc227d792"
    }
  },
  {
    "ts": null,
    "headline": "Amgen shows 20% weight loss in once-monthly injectable MariTide",
    "summary": "Amgen's latest once-monthly weight loss drug data looks \"OK,\" analysts say, as its path to approval still remains murky.",
    "url": "https://finnhub.io/api/news?id=fc9241ad543c19d15f2478738235cd11fd04e617fa2164d7fdf66fb884310f66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732630617,
      "headline": "Amgen shows 20% weight loss in once-monthly injectable MariTide",
      "id": 131636575,
      "image": "https://s.yimg.com/ny/api/res/1.2/qPrurmHpj6AEFYfe5D4gJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-09/40d85280-7b7a-11ef-be67-e5cf7ffe12b0",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen's latest once-monthly weight loss drug data looks \"OK,\" analysts say, as its path to approval still remains murky.",
      "url": "https://finnhub.io/api/news?id=fc9241ad543c19d15f2478738235cd11fd04e617fa2164d7fdf66fb884310f66"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Mixed Premarket Tuesday",
    "summary": "Health care stocks were mixed premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) was 0.",
    "url": "https://finnhub.io/api/news?id=e8f6c3901eb1ecc3702fa9618228913555a0a04faea8cb842eaf3a19264f0bac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732630467,
      "headline": "Sector Update: Health Care Stocks Mixed Premarket Tuesday",
      "id": 131654576,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Health care stocks were mixed premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) was 0.",
      "url": "https://finnhub.io/api/news?id=e8f6c3901eb1ecc3702fa9618228913555a0a04faea8cb842eaf3a19264f0bac"
    }
  },
  {
    "ts": null,
    "headline": "Medicare Could Pay for Wegovy. Don’t Count On It.",
    "summary": "Medicare Could Pay for Wegovy. Don’t Count On It.",
    "url": "https://finnhub.io/api/news?id=eb37f473c8c35a10cad0dc54d3b11f86646ca1db14b3bc544d2471b214b41a82",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732628940,
      "headline": "Medicare Could Pay for Wegovy. Don’t Count On It.",
      "id": 131774959,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Medicare Could Pay for Wegovy. Don’t Count On It.",
      "url": "https://finnhub.io/api/news?id=eb37f473c8c35a10cad0dc54d3b11f86646ca1db14b3bc544d2471b214b41a82"
    }
  },
  {
    "ts": null,
    "headline": "Update: Amgen Says Phase 2 Study Shows MariTide Achieves up to 20% Weight Loss in One Year",
    "summary": "(Updates with additional details throughout the story and the latest stock movement in the seventh paragraph.",
    "url": "https://finnhub.io/api/news?id=1da5339c5574f45944d0689726d767751b04aaafce67f6def419bdefd49226d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732628896,
      "headline": "Update: Amgen Says Phase 2 Study Shows MariTide Achieves up to 20% Weight Loss in One Year",
      "id": 131654577,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "(Updates with additional details throughout the story and the latest stock movement in the seventh paragraph.",
      "url": "https://finnhub.io/api/news?id=1da5339c5574f45944d0689726d767751b04aaafce67f6def419bdefd49226d7"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau",
    "summary": "On Tuesday, Amgen Inc (NASDAQ:AMGN) stock fell during the premarket session after the company released long-anticipated data from the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) in obese patients. The company said that MariTide demonstrated up to ~20% average weight loss at one year (52 weeks) without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks. Amgen’s stock dropped as the results seemed to fall short of Wall Street’s high ex",
    "url": "https://finnhub.io/api/news?id=36b742157bd09f40344e8b9b2e9d0c3807f21ff60658a5e7e345bac21b58cdc4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732628216,
      "headline": "Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau",
      "id": 131654579,
      "image": "https://media.zenfs.com/en/Benzinga/42a8ae7e294edee3836a9554e9a0f4aa",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "On Tuesday, Amgen Inc (NASDAQ:AMGN) stock fell during the premarket session after the company released long-anticipated data from the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) in obese patients. The company said that MariTide demonstrated up to ~20% average weight loss at one year (52 weeks) without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks. Amgen’s stock dropped as the results seemed to fall short of Wall Street’s high ex",
      "url": "https://finnhub.io/api/news?id=36b742157bd09f40344e8b9b2e9d0c3807f21ff60658a5e7e345bac21b58cdc4"
    }
  },
  {
    "ts": null,
    "headline": "Amgen falls after obesity study results",
    "summary": "Investing.com -- Shares of Amgen (NASDAQ: NASDAQ:AMGN) dropped 12% Tuesday following the release of Phase 2 trial results for its obesity drug candidate, MariTide (formerly AMG 133).",
    "url": "https://finnhub.io/api/news?id=4bdeeaade8e091bb157be08cf5bf79b1194c04b5e811d539eadd6a1baf3c6afc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732626691,
      "headline": "Amgen falls after obesity study results",
      "id": 131654581,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Investing.com -- Shares of Amgen (NASDAQ: NASDAQ:AMGN) dropped 12% Tuesday following the release of Phase 2 trial results for its obesity drug candidate, MariTide (formerly AMG 133).",
      "url": "https://finnhub.io/api/news?id=4bdeeaade8e091bb157be08cf5bf79b1194c04b5e811d539eadd6a1baf3c6afc"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY",
    "summary": "Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly AMG 133), an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently. In people living with obesity or overweight without Type 2 diabetes, MariTide demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks.1",
    "url": "https://finnhub.io/api/news?id=78b4396ac3f29d046a7e63710997e1de87d00c9a58f00bda1e69690b8de6cb00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732622700,
      "headline": "AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY",
      "id": 131631859,
      "image": "https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly AMG 133), an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently. In people living with obesity or overweight without Type 2 diabetes, MariTide demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks.1",
      "url": "https://finnhub.io/api/news?id=78b4396ac3f29d046a7e63710997e1de87d00c9a58f00bda1e69690b8de6cb00"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM",
    "summary": "Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024, to discuss data from the 52-week, Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) and progress on its development program. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.",
    "url": "https://finnhub.io/api/news?id=be2a8a8115ea83d4467de5594b18cc64dd0fdbea3940645c9d33d36acfcc3a49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732622400,
      "headline": "AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM",
      "id": 131631860,
      "image": "https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024, to discuss data from the 52-week, Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) and progress on its development program. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.",
      "url": "https://finnhub.io/api/news?id=be2a8a8115ea83d4467de5594b18cc64dd0fdbea3940645c9d33d36acfcc3a49"
    }
  },
  {
    "ts": null,
    "headline": "Amgen drags Dow lower after weight-loss drug data disappoints Wall Street",
    "summary": "Amgen drags Dow lower after weight-loss drug data disappoints Wall Street",
    "url": "https://finnhub.io/api/news?id=8be8309dddc98e7973fe29948468aa1c163308d09055728de786d70667e676f0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732618188,
      "headline": "Amgen drags Dow lower after weight-loss drug data disappoints Wall Street",
      "id": 131777142,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen drags Dow lower after weight-loss drug data disappoints Wall Street",
      "url": "https://finnhub.io/api/news?id=8be8309dddc98e7973fe29948468aa1c163308d09055728de786d70667e676f0"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.",
    "summary": "Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.",
    "url": "https://finnhub.io/api/news?id=e7302089422895c4eb7a4cb09b28e8a6dd435e5c1f542d55c404a5b96eba88f6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732612500,
      "headline": "Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.",
      "id": 131635985,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.",
      "url": "https://finnhub.io/api/news?id=e7302089422895c4eb7a4cb09b28e8a6dd435e5c1f542d55c404a5b96eba88f6"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test",
    "summary": "Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test",
    "url": "https://finnhub.io/api/news?id=96eee396a6af32f7101047b8642516f464257cb0e026598ae460ce7adc01ab71",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732611270,
      "headline": "Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test",
      "id": 131635960,
      "image": "",
      "related": "AMGN",
      "source": "DowJones",
      "summary": "Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test",
      "url": "https://finnhub.io/api/news?id=96eee396a6af32f7101047b8642516f464257cb0e026598ae460ce7adc01ab71"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: GM, Ford, Amgen, Eli Lilly, Super Micro, Rivian, Analog Devices, Kohl’s, and More",
    "summary": "These Stocks Are Moving the Most Today: GM, Ford, Amgen, Eli Lilly, Super Micro, Rivian, Analog Devices, Kohl’s, and More",
    "url": "https://finnhub.io/api/news?id=458b1e3833fa0867ed1eb77246e5bded5bddcdf4bbfca9a178f2554d9037115c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732614600,
      "headline": "These Stocks Are Moving the Most Today: GM, Ford, Amgen, Eli Lilly, Super Micro, Rivian, Analog Devices, Kohl’s, and More",
      "id": 131638488,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "These Stocks Are Moving the Most Today: GM, Ford, Amgen, Eli Lilly, Super Micro, Rivian, Analog Devices, Kohl’s, and More",
      "url": "https://finnhub.io/api/news?id=458b1e3833fa0867ed1eb77246e5bded5bddcdf4bbfca9a178f2554d9037115c"
    }
  },
  {
    "ts": null,
    "headline": "Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms",
    "summary": "Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms",
    "url": "https://finnhub.io/api/news?id=8feb33640cf82775875c4286d7e6950d616e0e803074d835aad31ad703da480f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732614360,
      "headline": "Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms",
      "id": 131638489,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms",
      "url": "https://finnhub.io/api/news?id=8feb33640cf82775875c4286d7e6950d616e0e803074d835aad31ad703da480f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen, Boeing share losses lead Dow's 200-point fall",
    "summary": "Amgen, Boeing share losses lead Dow's 200-point fall",
    "url": "https://finnhub.io/api/news?id=81e02a280eef9cad20a7b97d41b9c68ec485d9d91fc0999a95b19d0907fe0f57",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732614300,
      "headline": "Amgen, Boeing share losses lead Dow's 200-point fall",
      "id": 131636896,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen, Boeing share losses lead Dow's 200-point fall",
      "url": "https://finnhub.io/api/news?id=81e02a280eef9cad20a7b97d41b9c68ec485d9d91fc0999a95b19d0907fe0f57"
    }
  },
  {
    "ts": null,
    "headline": "Amgen : MariTide Topline Phase 2 Results",
    "summary": "MariTide Update November 26, 2024 Today's Presenters Bob...",
    "url": "https://finnhub.io/api/news?id=c1b35d2a129bd58287e0d0ae34b38e43a3757de4221facd5bed0c1313128ece7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732610405,
      "headline": "Amgen : MariTide Topline Phase 2 Results",
      "id": 131633054,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "MariTide Update November 26, 2024 Today's Presenters Bob...",
      "url": "https://finnhub.io/api/news?id=c1b35d2a129bd58287e0d0ae34b38e43a3757de4221facd5bed0c1313128ece7"
    }
  },
  {
    "ts": null,
    "headline": "Weight-loss stocks get a boost from new Biden proposal on drug coverage, but will it hold up?",
    "summary": "Weight-loss stocks get a boost from new Biden proposal on drug coverage, but will it hold up?",
    "url": "https://finnhub.io/api/news?id=d4afc9ee7e74c1fac9babb94c2d21dc405b024fe54866aae7df2331498ce4f43",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732605248,
      "headline": "Weight-loss stocks get a boost from new Biden proposal on drug coverage, but will it hold up?",
      "id": 131635987,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Weight-loss stocks get a boost from new Biden proposal on drug coverage, but will it hold up?",
      "url": "https://finnhub.io/api/news?id=d4afc9ee7e74c1fac9babb94c2d21dc405b024fe54866aae7df2331498ce4f43"
    }
  }
]